New genetic techniques to combat lung cancer

Apr 25, 2008

New results on genetic techniques that are helping doctors diagnose and treat lung cancer were released today at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) in Geneva, Switzerland.

In one report, Israeli researchers from Rosetta Genomics, a biotech company developing microRNA-based technologies for diagnostic and therapeutic applications, describe a test that helps make crucial distinctions between types of lung cancer. The researchers show the method can accurately distinguish between squamous and non-squamous forms of non-small-cell lung cancer based on the levels of different microRNA molecules found in tissue samples.

MicroRNAs are short RNA molecules that regulate many cancer-related processes. "Recently, with the launch of new targeted therapies for non-squamous, non-small-cell lung cancer, the importance of accurate, objective diagnosis has taken center stage. The ability of physicians to accurately differentiate squamous from non-squamous NSCLC may be used as important treatment guide," said Dr. Maya Gottfried, member of Rosetta Genomics Medical Advisory Board and head of the Lung Cancer Unit at Meir Medical Center in Kfar Saba, Israel. For example some treatments for non-squamous non-small-cell lung cancer can be deadly in patients with the squamous form of the disease. Researchers expect the test to be approved for use during 2008.

In another report (Abstract No. 106PD; Friday 25th April, 08:00), Italian researchers show that genetic analysis can help identify patients who are at high risk of relapse after surgery to remove lung cancer. Dr. Guido Natoli from Regina Elena National Cancer Institute in Rome reports that the three-gene 'signature' can help oncologists choose the best drug to treat with.

"The results are preliminary, but I think our signature may allow the oncologists to classify patients with stage I non-small-cell lung cancer who underwent curative surgical resection in high or low risk molecular category, beyond conventional predictors," says Dr. Natoli.

His group's test includes the gene LCK, which is an important marker of immune cell anticancer activity, DUSP-6 which regulates a signaling pathway involved in cancer spread, and ERCC1, which is thought to be a significant prognostic and therapeutic biomarker in non-small-cell lung cancer. "By gathering these findings we can improve not only the prognostic stratification of patients, but also the choice of the more appropriate adjuvant drug after surgery," Dr. Natoli said.

Source: European Society for Medical Oncology

Explore further: PDE-5 inhibitors tied to prostate cancer biochemical recurrence

add to favorites email to friend print save as pdf

Related Stories

Microsoft profit dips as revenue rises

2 hours ago

Microsoft on Monday reported that its quarterly profit dipped as revenue increased with help from sales of Surface tablets, Xbox One consoles and cloud services.

Black hole chokes on a swallowed star

3 hours ago

A five-year analysis of an event captured by a tiny telescope at McDonald Observatory and followed up by telescopes on the ground and in space has led astronomers to believe they witnessed a giant black hole ...

Montana oil spill estimate lowered to 30,000 gallons

3 hours ago

Authorities have lowered their estimate of how much oil spilled from a broken pipeline beneath the Yellowstone River in eastern Montana, briefly contaminating the water supply of a city downstream.

Recommended for you

Cancer fear can impact screening uptake

18 hours ago

People who worry about cancer are more likely to want to get screened for colon cancer, but feeling uncomfortable at the thought of cancer makes them less likely to actually go for the test, finds new UCL-led ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.